Content specific to this active ingredient… Drug Information Prescribing and patient information from leading authorities Drug Master Files Type 2 master files on file at the FDA Safety Information For prescription drugs containing this active ingredient Exclusivity Patent and market exclusivity data Federal Register FR search results for this API FDA Approved Labelling Information found in this drug's package inserts Research Links Chemical identification and research citations Title 21 Code of Federal Regulations FDA regulations for this API

FDA Approval Activities for this Drug… Canasa (mesalamine) Suppositories, Axcan Scandipharm NDA 21-252/S2 10/14/03 10/17/03 | Canasa (mesalamine) Suppositories, Axcan Scandipharm NDA 21-252 | Pentasa (Mesalamine) Capsules Roberts NDA 20-049/S006 MESALAMINE Capsule, Extended Release; 250MG PENTASA SHIRE | 019618 MESALAMINE Enema; Rectal 4GM/60ML ROWASA SOLVAY | 021252 MESALAMINE Suppository; Rectal 500MG CANASA AXCAN SCANDIPHARM | 019651 MESALAMINE Tablet, Delayed Release; 400MG ASACOL PROCTER AND GAMBLE Pentasa (meslamine) Controlled Release Capsules, Shire Pharmaceutical, Control Supplement | Mesalamine Rectal Suspension, Clay-Park Labs, Approval | CANASA (mesalamine) Suppository, Axcan Scandipharm, Labeling Revision | Canasa (Mesalamine, USP) Rectal Suppositories, Axcan Scandipharm, New Dosage Regimen | ROWASA (mesalamine) Rectal Suspension Enema, Solvay Pharma, Labeling Revision | Canasa (mesalamine) Suppository, Axcan Scandipharm, Labeling Revision | Pentasa (mesalamine) Controlled-Release Capsules, Shire Dev., Labeling Revision | Lialda (mesalamine) Delayed Release Tablets, Shire Development, Approval | Asacol (mesalamine) Delayed Release Tablets, Procter & Gamble Pharma, Labeling Revision | Mesalamine Rectal Suspension, Perrigo Co., Control Supplement | Pentasa (mesalamine) Controlled-Release Capsules, Shire Dev., Labeling Revision | CANASA (mesalamine) Suppository, Axcan Scandipharma Inc., Package Change | Tradename To Be Determined (mesalamine) Delayed-Release Tablets, Procter & Gamble Pharmaceuticals, Approval | Rowasa (mesalamine) Enema, Alaven Pharmaceutical, LLC, Formulation Revision | Apriso (mesalamine) Extended-Release Capsules, Salix Pharmaceuticals, Inc., Approval | Asacol HD (mesalamine) Delayed-Release Tablets, Procter & Gamble Pharmaceuticals, Inc., Labeling Revision | Lialda (mesalamine) Delayed-Release Tablets, Shire Development Inc., Labeling Revision | Lialda (mesalamine) Delayed-Release Tablet, Shire Development Inc., Labeling Revision | Lialda (mesalamine) Delayed-Release Tablets, Shire Development, Inc., Efficacy Supplement with Clinical Data to Support ^ FDA's latest approval appears at the bottom of this list. ^                                                                       A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | For Industry | DMF Index | Pharma Job Search | Pharma Company News | Best Phone © 2012 Betterchem.com